A multicenter, phase II study of Bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma
Authors:
- 25 June 2010
- journal article
- research article
- Published by Springer Nature in Investigational New Drugs
- Vol. 29 (6) , 1475-1481
Abstract
Purpose The transcription factor nuclear factor-kB (NFkB) is implicated in gastric cancer carcinogenesis and survival, and its inhibition by proteosome inhibition is associated with preclinical gastric cancer anti-tumor activity. We examined the single agent efficacy of bortezomib, a selective proteasome inhibitor, in gastric adenocarcinoma. Experimental Design We performed a phase II trial of bortezomib in patients with advanced gastric adenocarcinoma. Bortezomib 1.3 mg/m2 was administered on days 1, 4, 8, and 11 every 21 days. The primary endpoint was objective response rate(RR); the null hypothesis was RR Results We enrolled 16 patients (15 evaluable for response) from four institutions. No patients demonstrated an objective response(95% CI, 0–22%); one patient achieved stable disease. Fourteen out of 16 patients experienced ≥ grade 2 toxicity. The most common toxicity was fatigue in six patients (n = 4 grade 2, n = 2 grade 3). Seven patients experienced neuropathy (n = 5 grade 1, and 1 each grade 2 and 3). Seven (60%) had high cytoplasmic staining for NFkB. Conclusions Single agent bortezomib is inactive in metastatic gastric adenocarcinoma and should not be pursued. Future study of proteasome inhibition in gastric adenocarcinoma should be considered in combination with targeted inhibition of other non-overlapping oncogenic pathways as a potential rational approach.Keywords
This publication has 38 references indexed in Scilit:
- A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group studyGynecologic Oncology, 2009
- Oncogenic Pathway Combinations Predict Clinical Prognosis in Gastric CancerPLOS Genetics, 2009
- Proteasome Inhibition Activates Epidermal Growth Factor Receptor (EGFR) and EGFR-Independent Mitogenic Kinase Signaling Pathways in Pancreatic Cancer CellsClinical Cancer Research, 2008
- Bortezomib, Paclitaxel, and Carboplatin as a First-Line Regimen for Patients with Metastatic Esophageal, Gastric, and Gastroesophageal Cancer: Phase II Results from the North Central Cancer Treatment Group (N044B)Journal of Thoracic Oncology, 2008
- Antitumor effects and drug interactions of the proteasome inhibitor bortezomib (PS341) in gastric cancer cellsAnti-Cancer Drugs, 2007
- Nuclear factor-κB in cancer development and progressionNature, 2006
- Nuclear Factor-κB Activation Correlates with Better Prognosis and Akt Activation in Human Gastric CancerClinical Cancer Research, 2005
- Helicobacter pylori-dependent NF-kappa B activation in newly established Mongolian gerbil gastric cancer cell linesCancer Science, 2005
- Phase II Trial of Bortezomib for Patients With Advanced Renal Cell CarcinomaJournal of Clinical Oncology, 2004
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000